Featured Research

from universities, journals, and other organizations

New Strategies To Improve Treatment And Ultimately Prevent Heart Failure In Children

Date:
July 7, 2009
Source:
Indiana University
Summary:
New basic science and clinical research aims to improve treatment of, and ultimately to prevent, the congenital defects and damage acquired after birth that cause heart failure in children.

Structural cardiovascular abnormalities present at birth are the leading cause of heart failure in children. Nearly half a million children in the United States have structural heart problems ranging in severity from relatively simple issues, such as small holes between chambers of the heart, to very severe malformations, including complete absence of one or more chambers or valves.

The July issue of the journal Pediatric Cardiology focuses on a recent meeting of pediatric cardiology experts from around the world who gathered at the Indiana University School of Medicine and Riley Hospital for Children for the inaugural Riley Heart Center Symposium on Cardiac Development. The experts presented new basic science and clinical research to improve treatment of, and ultimately to prevent, the congenital defects and damage acquired after birth that cause heart failure in children.

The symposium focused on the growth of the ventricular wall in development and disease, and on the diagnosis and treatment of non-compaction of the left ventricle - an abnormality of the major pumping chamber of the heart which often leads to heart failure. Both are areas of ongoing study by the Riley Heart Research Center.

"A wide spectrum of congenital and acquired cardiac injuries can give rise to childhood heart failure. To advance our ability to treat heart failure in children, it is of critical importance to develop an understanding of the cellular and molecular mechanisms underlying the genesis of congenital heart defects, and to develop an understanding of the molecular processes that negatively impact upon heart muscle cell function and survival during the progression of childhood heart failure," wrote symposium organizer Loren Field, Ph.D., professor of medicine, and pediatrics, who directs the Riley Heart Research Center and convened the symposium. The Riley Heart Research Center is located in the Herman B Wells Center for Pediatric Research in the Department of Pediatrics at the IU School of Medicine and Riley Hospital.

Although there are fewer children than adults with this serious and sometimes fatal condition, the societal issues and health-care costs of heart failure, are more significant in young patients given the longer lifespan of children.

Growth of the heart during development is characterized by the differentiation and proliferation of beating cardiac muscle cells. After birth there is a transition which limits the ability of the heart to regenerate itself following injury or disease. In his presentation and paper, Dr. Field described the innovative cell cycle-based strategies he employs in the laboratory to stimulate heart muscle tissue to repair itself resulting in regeneration of damaged tissue.

Designing and testing genetically engineered mice, Weinian Shou, Ph.D., associate professor of pediatrics, reported that he and colleagues are gaining a greater understanding of the molecular and genetic mechanisms of noncompaction of the left ventricle, with the ultimate goal of finding potential new therapies.

In a study designed to evaluate the outcomes of children with noncompaction of the left ventricle, Eric Ebenroth, M.D., associate clinical professor of pediatrics, followed 46 Riley Hospital patients with this type of heart failure. He found that when the disease presents before the child reaches his first birthday, the child has a much lower chance for survival. Dr. Ebenroth and colleagues now are working to identify additional risk factors associated with the increased likelihood of death in these patients in the hopes of improving their outcomes.

The symposium faculty included leading clinical and basic scientists from the United States, Germany, Austria, England, the Netherlands, France and Spain. Pediatric Cardiology contains 16 studies presented at the symposium.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University. "New Strategies To Improve Treatment And Ultimately Prevent Heart Failure In Children." ScienceDaily. ScienceDaily, 7 July 2009. <www.sciencedaily.com/releases/2009/07/090707131826.htm>.
Indiana University. (2009, July 7). New Strategies To Improve Treatment And Ultimately Prevent Heart Failure In Children. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/07/090707131826.htm
Indiana University. "New Strategies To Improve Treatment And Ultimately Prevent Heart Failure In Children." ScienceDaily. www.sciencedaily.com/releases/2009/07/090707131826.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins